. 2015 Mar 5;519(7541):57-62.

doi: 10.1038/nature14228. Epub 2015 Feb 25.

A gp130-Src-YAP module links inflammation to epithelial regeneration

Koji Taniguchi¹, Li-Wha Wu², Sergei I Grivennikov³, Petrus R de Jong⁴, Ian Lian⁵, Fa-Xing Yu⁶, Kepeng Wang⁷, Samuel B Ho⁸, Brigid S Boland⁹, John T Chang⁹, William J Sandborn⁹, Gary Hardiman¹⁰, Eyal Raz⁴, Yoshihiko Maehara¹¹, Akihiko Yoshimura¹², Jessica Zucman-Rossi¹³, Kun-Liang Guan¹⁴, Michael Karin¹⁵

Affiliations

¹ 1] Laboratory of Gene Regulation and Signal Transduction, University of California, San Diego, La Jolla, California 92093, USA [2] Departments of Pharmacology and Pathology, University of California, San Diego, La Jolla, California 92093, USA [3] Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka 812-8582, Japan [4] Department of Microbiology and Immunology, Keio University School of Medicine, Tokyo 160-8582, Japan.
² 1] Laboratory of Gene Regulation and Signal Transduction, University of California, San Diego, La Jolla, California 92093, USA [2] Institute of Molecular Medicine, College of Medicine, National Cheng Kung University, Tainan 70101, Taiwan.
³ 1] Laboratory of Gene Regulation and Signal Transduction, University of California, San Diego, La Jolla, California 92093, USA [2] Fox Chase Cancer Center, Cancer Prevention and Control Program, Philadelphia, Pennsylvania 19111, USA.
⁴ Department of Medicine, University of California, San Diego, La Jolla, California 92093, USA.
⁵ 1] Departments of Pharmacology and Pathology, University of California, San Diego, La Jolla, California 92093, USA [2] Moores Cancer Center, University of California, San Diego, La Jolla, California 92093, USA [3] Department of Biology, Lamar University, PO Box 10037, Beaumont, Texas 77710, USA.
⁶ 1] Departments of Pharmacology and Pathology, University of California, San Diego, La Jolla, California 92093, USA [2] Moores Cancer Center, University of California, San Diego, La Jolla, California 92093, USA [3] Children's Hospital and Institutes of Biomedical Sciences, Fudan University, Shanghai 200032, China.
⁷ Laboratory of Gene Regulation and Signal Transduction, University of California, San Diego, La Jolla, California 92093, USA.
⁸ Department of Medicine, VA San Diego Healthcare System, San Diego, California 92161, USA.
⁹ Inflammatory Bowel Disease Center, Division of Gastroenterology, Department of Medicine, School of Medicine, University of California, San Diego, La Jolla, California 92093, USA.
¹⁰ 1] Department of Medicine, Medical University of South Carolina, Charleston, South Carolina 29425, USA [2] CSRC and BIMRC, San Diego State University, San Diego, California 92182, USA.
¹¹ Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka 812-8582, Japan.
¹² 1] Department of Microbiology and Immunology, Keio University School of Medicine, Tokyo 160-8582, Japan [2] Japan Science and Technology Agency, CREST, Tokyo 102-0076, Japan.
¹³ 1] Inserm, UMR 1162, Génomique fonctionnelle des tumeurs solides, IUH, Paris 75010, France [2] Université Paris Descartes, Labex Immuno-oncology, Sorbonne Paris Cité, Faculté de Medicine, Paris 75006, France.
¹⁴ 1] Departments of Pharmacology and Pathology, University of California, San Diego, La Jolla, California 92093, USA [2] Moores Cancer Center, University of California, San Diego, La Jolla, California 92093, USA.
¹⁵ 1] Laboratory of Gene Regulation and Signal Transduction, University of California, San Diego, La Jolla, California 92093, USA [2] Departments of Pharmacology and Pathology, University of California, San Diego, La Jolla, California 92093, USA [3] Moores Cancer Center, University of California, San Diego, La Jolla, California 92093, USA.

PMID: 25731159
PMCID: PMC4447318
DOI: 10.1038/nature14228

A gp130-Src-YAP module links inflammation to epithelial regeneration

Koji Taniguchi et al. Nature. 2015.

. 2015 Mar 5;519(7541):57-62.

doi: 10.1038/nature14228. Epub 2015 Feb 25.

Authors

Affiliations

¹ 1] Laboratory of Gene Regulation and Signal Transduction, University of California, San Diego, La Jolla, California 92093, USA [2] Departments of Pharmacology and Pathology, University of California, San Diego, La Jolla, California 92093, USA [3] Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka 812-8582, Japan [4] Department of Microbiology and Immunology, Keio University School of Medicine, Tokyo 160-8582, Japan.
² 1] Laboratory of Gene Regulation and Signal Transduction, University of California, San Diego, La Jolla, California 92093, USA [2] Institute of Molecular Medicine, College of Medicine, National Cheng Kung University, Tainan 70101, Taiwan.
³ 1] Laboratory of Gene Regulation and Signal Transduction, University of California, San Diego, La Jolla, California 92093, USA [2] Fox Chase Cancer Center, Cancer Prevention and Control Program, Philadelphia, Pennsylvania 19111, USA.
⁴ Department of Medicine, University of California, San Diego, La Jolla, California 92093, USA.
⁵ 1] Departments of Pharmacology and Pathology, University of California, San Diego, La Jolla, California 92093, USA [2] Moores Cancer Center, University of California, San Diego, La Jolla, California 92093, USA [3] Department of Biology, Lamar University, PO Box 10037, Beaumont, Texas 77710, USA.
⁶ 1] Departments of Pharmacology and Pathology, University of California, San Diego, La Jolla, California 92093, USA [2] Moores Cancer Center, University of California, San Diego, La Jolla, California 92093, USA [3] Children's Hospital and Institutes of Biomedical Sciences, Fudan University, Shanghai 200032, China.
⁷ Laboratory of Gene Regulation and Signal Transduction, University of California, San Diego, La Jolla, California 92093, USA.
⁸ Department of Medicine, VA San Diego Healthcare System, San Diego, California 92161, USA.
⁹ Inflammatory Bowel Disease Center, Division of Gastroenterology, Department of Medicine, School of Medicine, University of California, San Diego, La Jolla, California 92093, USA.
¹⁰ 1] Department of Medicine, Medical University of South Carolina, Charleston, South Carolina 29425, USA [2] CSRC and BIMRC, San Diego State University, San Diego, California 92182, USA.
¹¹ Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka 812-8582, Japan.
¹² 1] Department of Microbiology and Immunology, Keio University School of Medicine, Tokyo 160-8582, Japan [2] Japan Science and Technology Agency, CREST, Tokyo 102-0076, Japan.
¹³ 1] Inserm, UMR 1162, Génomique fonctionnelle des tumeurs solides, IUH, Paris 75010, France [2] Université Paris Descartes, Labex Immuno-oncology, Sorbonne Paris Cité, Faculté de Medicine, Paris 75006, France.
¹⁴ 1] Departments of Pharmacology and Pathology, University of California, San Diego, La Jolla, California 92093, USA [2] Moores Cancer Center, University of California, San Diego, La Jolla, California 92093, USA.
¹⁵ 1] Laboratory of Gene Regulation and Signal Transduction, University of California, San Diego, La Jolla, California 92093, USA [2] Departments of Pharmacology and Pathology, University of California, San Diego, La Jolla, California 92093, USA [3] Moores Cancer Center, University of California, San Diego, La Jolla, California 92093, USA.

PMID: 25731159
PMCID: PMC4447318
DOI: 10.1038/nature14228

Abstract

Inflammation promotes regeneration of injured tissues through poorly understood mechanisms, some of which involve interleukin (IL)-6 family members, the expression of which is elevated in many diseases including inflammatory bowel diseases and colorectal cancer. Here we show in mice and human cells that gp130, a co-receptor for IL-6 cytokines, triggers activation of YAP and Notch, transcriptional regulators that control tissue growth and regeneration, independently of the gp130 effector STAT3. Through YAP and Notch, intestinal gp130 signalling stimulates epithelial cell proliferation, causes aberrant differentiation and confers resistance to mucosal erosion. gp130 associates with the related tyrosine kinases Src and Yes, which are activated on receptor engagement to phosphorylate YAP and induce its stabilization and nuclear translocation. This signalling module is strongly activated upon mucosal injury to promote healing and maintain barrier function.

PubMed Disclaimer

Figures

**Extended Data Figure 1. gp130^Act expression and intestinal phenotype**
(a) Schematic diagram of the *villin-gp130^Act* transgenic (Tg) construct and the gp130^Act and gp130^SA variants. (b) Expression of gp130^Act in the *villin-gp130^Act* jejunum was confirmed by RT-PCR with specific primers for human gp130. Cyclophilin (CPH) was used as an internal control. (c) Representative images of WT and *villin-gp130^Act* intestines. c-Myc and CyclinD1 (d) and TUNEL (red: TUNEL; blue: DAPI) (e) staining of paraffin-embedded sections of WT and *villin-gp130^Act* small intestines from 3-month old mice. Positive cells were enumerated in each villus or crypt (n=6). Data represent averages ± SD. *P < 0.05. (f) MMP7, AB and ChrA positive cells in WT and *villin-gp130^Act* small intestines were enumerated in each villus or crypt (n=6). Data represent averages ± SD. *P < 0.05. (g) Paraffin embedded sections of WT and *villin-gp130^Act* small intestines were analyzed by PAS and lysozyme staining. Positive cells were enumerated in each villus or crypt (n=6). Data represent averages ± SD. *P < 0.05. (h) Cryptdin mRNA in WT and *villin-gp130^Act* jejunum was detected by *in situ* hybridization. (i) Transmission electron microscopy (TEM) of the apical surface of WT and Tg small intestines. Scale bars represent 100 μm (**d, e, g, h**) and 1 μm (i) and all data are representative of at least 2–3 independent experiments.

**Extended Data Figure 2. Aberrant intestinal differentiation and activation of gp130 effectors in *gp130^Act* mice**
(a) Paraffin embedded sections of WT and *villin-gp130^Act* small intestines were analyzed by CD45 staining. (b) Lysates of WT and *villin-gp130^Act* jejuna were prepared, and expression of IL-6 and TNF mRNAs was analyzed by qRT-PCR (n=3). Results are averages ± SEM. *P < 0.05. (c) H&E and PAS staining of paraffin-embedded sections of WT and *villin-gp130^Act* large intestines. (d) P-STAT1, P-ERK1/2, P-S6, and CD44 C-terminal stainings of paraffin-embedded sections of WT and *villin-gp130^Act* small intestines. Positive cells were enumerated in each villus or crypt (n=4). Data represent averages ± SD. *P < 0.05. (e) YAP, Ki67, and P-STAT3 stainings of paraffin-embedded sections of WT and *villin-gp130^Act* large intestines. Positive cells were enumerated in each crypt (n=4). Data represent averages ± SD. *P < 0.05. Scale bars represent 100 μm (**a, c–e**) and all data are representative of at least 2–3 independent experiments.

**Extended Data Figure 3. IL-6 and gp130 induce Notch and YAP activation in intestinal organoids and cancer cells, and gene expression analysis of intestinal crypts**
(**a,b**) WT and *villin-gp130^Act* organoids were cultured, their RNA extracted, and expression of the indicated mRNA species was measured by qRT-PCR (n=3). Results are averages ± SEM. *P < 0.05. (c) Appearance of WT and *villin-gp130^Act* small intestinal organoids cultured in standard EGF/Noggin/R-spondin 1 medium. (d) Nuclei of T84 colon cancer cells transfected with either empty vector (EV) or a vector encoding superactive gp130 (gp130^SA) were lysed and subjected to IB analysis with the indicated antibodies. Lamin A, a nuclear marker. Actin, a loading control. (e) Lysates of serum-starved SW480 (upper) or DLD1 (lower) colon cancer cells treated for 0–480 min with IL-6 at 50 ng/ml were subjected to immunoblot analysis using the indicated antibodies. (f) Nuclei of serum-starved HT29 colon cancer cells treated for 24 hrs with IL-6 at 0–50 ng/ml were lysed and subjected to IB analysis with the indicated antibodies. HDAC, a nuclear marker and loading control. (g) Lysates of primary mouse hepatocytes treated for 0–120 min with IL-6 at 50 ng/ml were subjected to immunoblot analysis using the indicated antibodies. (h) Microarray analysis was performed using the Illumina MouseWG-6 v2 Expression BeadChip on RNA extracted from WT and *villin-gp130^Act* small intestinal crypts (n=3/group). Data were normalized and analyzed as described and expression of the indicated genes is shown as fold-induction compared to WT crypts. (i) RNA was extracted from of WT and *villin-gp130^Act* small intestinal organoids, and Areg mRNA expression was measured by qRT-PCR (n=3). Results are averages ± SEM. *P < 0.05. Scale bars represent 100 μm (c) and all data are representative of at least 2–3 independent experiments.

**Extended Data Figure 4. Aberrant intestinal differentiation in *gp130^Act* mice depends on Notch and YAP but not on STAT3**
(a) MMP7 staining of paraffin-embedded sections of control and DBZ-treated (10 μmol/kg) *villin-gp130^Act* small intestines. Positive cells were enumerated in each crypt (n=3). Data represent averages ± SD. *P < 0.05. (b) MMP7 and lysozyme staining of paraffin-embedded sections of *villin-gp130^Act* and *villin-gp130^Act/Yap^ΔIEC* small intestines. Positive cells were enumerated in each crypt (n=4). Data represent averages ± SD. *P < 0.05. (c) PAS, Ki67, YAP, P-STAT3, HES1 and MMP7 staining of paraffin-embedded sections of *villin-gp130^Act* and *villin-gp130^Act/Stat3^ΔIEC* small intestines. Positive cells were enumerated in each villus or crypt (n=4). Data represent averages ± SD. *P < 0.05. Scale bars represent 100 μm (**a–c**) and all data are representative of at least 2–3 independent experiments.

**Extended Data Figure 5. MEK and PI3K inhibitors have no effect on aberrant intestinal homeostasis in *gp130^Act* mice**
(a) PAS, Ki67, YAP, and P-ERK1/2 staining of paraffin-embedded sections of control and PD0325901-treated (25 mg/kg) *villin-gp130^Act* small intestines. Positive cells were enumerated in each villus or crypt (n=3). Data represent averages ± SD. *P < 0.05. (b) PAS, Ki67, YAP and P-S6 staining of paraffin-embedded sections of control and LY294002-treated (100 mg/kg) *villin-gp130^Act* small intestines. Positive cells were enumerated in each villus or crypt (n=3). Data represent averages ± SD. *P < 0.05. Scale bars represent 100 μm (**a, b**).

**Extended Data Figure 6. gp130 activates YAP via a Hippo-independent but tyrosine phosphorylation-dependent mechanism, and gp130 interacts with Src and Yes**
(a) Lysates of WT and *villin-gp130^Act* jejuna, which are the same as the ones in Fig. 2a, were analyzed for expression and phosphorylation of the indicated proteins. (b) Lysates of HT29 colon cancer cells transfected with either empty vector (EV), active gp130 (gp130^Act), or superactive gp130 (gp130^SA) were subjected to IB analysis with P-Src (Y419), total Src and GAPDH antibodies. GAPDH, a loading control. (c) Lysates of HCA7 colon cancer cells infected with EV, WT gp130, gp130^Act, or gp130^SA lentiviruses were immunoprecipitated with anti-YAP antibody and blotted with the indicated antibodies. (d) Lysates of HT29 colon cancer cells infected with EV, WT gp130, gp130^Act, or gp130^SA lentiviruses were IB analyzed for expression and phosphorylation of the indicated proteins. (e) Serum-starved HCT116 cells were stimulated with 10% FBS, IL-6 (100 ng/ml), or IL-11 (100 ng/ml) for 30 min. Total cell lysates were analyzed for expression and phosphorylation of the indicated proteins. (f) Left panel: P-Src and YAP staining of livers from untreated wild-type mice (control) and wild-type mice 48 hrs after partial hepatectomy (PH). Scale bars represent 100 μm. Middle panel: Lysates of livers from control mice and mice 48 hrs after PH were subjected to immunoblot analysis with the indicated antibodies. Right panel: Lysates of livers from vehicle (DMSO)-treated and PP2-treated mice 48 hrs after PH were subjected to immunoblot analysis with the indicated antibodies (g) upper: HEK293T cells were transfected with plasmids expressing FLAG-YAP. Twenty-four hrs after transfection, the cells were pre-treated for 1 hr with 0.1% DMSO (vehicle control), PP2 (10 μM) or AZD1480 (1 μM) and then were treated with 50 μg/ml cycloheximide for different time points. Total cell lysates were subjected to IB analysis with the indicated antibodies. lower: HEK293T cells were transfected with FLAG-YAP as above. Twenty-four hrs after transfection, the cells were pre-treated for 1 hr with 0.1% DMSO (vehicle control), AZD0530 (10 μM) or SU6656 (10 μM) and then were treated with 50 μg/ml cycloheximide for different time points. Total cell lysates were analyzed as above. (h) HEK293T cells were transfected with either empty or constitutively active (CA) Src expression vectors. After 48 hrs, the cells were lysed and expression of the indicated proteins determined by IB analysis. (i) HT29 cells were collected with or without 10 ng/ml IL-6 stimulation for 2 hrs. Lysates were analyzed by IB with the indicated antibodies. These are the loading controls for the data shown in Fig. 4e. (j) HEK293T cells were transfected with expression vectors encoding Src and FLAG-tagged gp130^Act, FLAG-tagged gp130^Act (Δ771-811), FLAG-tagged gp130^Act (Δ812-827) or empty vector. Cells were collected 48 hrs later. Cell lysates were IP’ed with FLAG antibody and analyzed by IB with the indicated antibodies. (k) Nuclei of T84 colon cancer cells transfected with empty vector (EV), gp130^Act, gp130^Act (Δ771-811) or gp130^Act (Δ812-827) expression vectors were prepared and subjected to IB analysis with the indicated antibodies. HDAC1, a nuclear marker and loading control. All data are representative of at least 2–3 independent experiments.

**Extended Data Figure 7. SFK activity is required for YAP activation**
(a) Tg mice (n=4/group) were treated with PP2 (5 mg/kg) or vehicle once a day for 5 days. Small intestines were isolated, sectioned and stained as indicated. Positive cells were enumerated in each villus or crypt. Data represent averages ± SD. *P < 0.05. (**b,c**) WT and *villin-gp130^Act* small intestinal organoids were treated with DMSO, AZD0530 (10 μM) (b), AZD1480 (1 μM) or DBZ (10 μM) (c) for 24 hrs, stained with YAP antibody and counter stained with DAPI and photographed under a fluorescent microscope. (d) WT and *villin-gp130^Act* small intestinal organoids were treated with DMSO, PP2 (10 μM) and AZD1480 (1 μM) for 24 hrs. Total cell lysates were subjected to IB analysis with the indicated antibodies. (e) Serum-starved HT29 cells were pre-treated for 1 hr with 0.1% DMSO (vehicle control), AZD1480 (10 μM) or PP2 (20 μM) prior to IL-6 (10 ng/ml) stimulation for 24 hrs. Nuclear extracts of HT29 cells treated without or with IL-6 in the absence or presence of AZD1480 or PP2 were subjected to IB analysis with the indicated antibodies. Lamin A, a nuclear marker; Actin, a loading control. (f) WT and *villin-gp130^Act* small intestinal organoids were treated with DMSO and AZD0530 (10 μM) for 24 hrs. Total cell lysates were subjected to IB analysis with the indicated antibodies. Scale bars represent 100 μm (**a–c**). All data are representative of at least 2–3 independent experiments.

**Extended Data Figure 8. gp130^Act confers DSS resistance, induces Notch receptors and ligands and improves barrier function**
(a) left: Representative images of WT and *villin-gp130^Act* large intestines taken 10 days after 3.0% DSS treatment. right: Colon length of WT and *villin-gp130^Act* mice before and after DSS treatment (before: n=5/group, after: n=4/group). Results are averages ± SEM. *P < 0.05. (b) Representative images of H&E stained paraffin-embedded colon sections prepared 10 days after DSS challenge of WT and Tg mice as described in Fig. 5a. Magnification bars: 100 μm. (c) Ki67 (left panels) and cleaved-caspase3 (right panels) stainings were performed on paraffin-embedded colon sections from WT and Tg mice at day 0 and 3 (Ki67) or 5 (cleaved-caspase3) after 3.0% DSS treatment. (d) Lysates of WT, *villin-gp130^Act*, *villin-gp130^Act/Yap^ΔIEC* and *villin-gp130^Act/Stat3^ΔIEC* colons were prepared, RNA was extracted and expression of the indicated mRNA species was analyzed by qRT-PCR (n=3/group). Results are averages ± SEM. *P < 0.05 (**e, f**) Gut barrier function in WT and *villin-gp130^Act* mice was examined by measurements of fecal albumin (WT: n=6, Tg: n=7) (e) and FITC-Dextran translocation to blood 4 hrs after oral gavage (WT: n=5, Tg: n=4) (f). Results are averages ± SEM. *P < 0.05. (g) TEM images of intestinal mucosa epithelial cell-cell junctions in WT and *villin-gp130^Act* small intestines. (h) C57BL/6 mice were given regular water or 2.5% DSS for 7 days. Colonic RNA was extracted on day 10, and expression of the indicated genes was analyzed by qRT-PCR (n=4). Results are averages ± SEM. *P < 0.05. (i) WT mice were given 2.5% DSS. Colonic lysates were prepared when indicated and IB analyzed for protein expression and phosphorylation. (j) Colon length of control and PP2-injected C57BL/6 mice after DSS treatment (n=6/group). Results are averages ± SEM. *P < 0.05. Scale bars represent 100 μm (**b, c**) and 500 nm (g).

**Extended Data Figure 9. Enhanced mucosal regeneration in *gp130^Act* mice depends on YAP and STAT3 but the two effectors control different genes, and YAP is required for *in vitro* scratch closure**
(a) Left: Body weight curves of DSS-treated *Yap^ΔIEC* (□, n=6) and *villin-gp130^Act/Yap^ΔIEC* (○, n=4) mice. Results are averages ± SD. *P < 0.05. Colon mucosal histology of *Yap^ΔIEC* (□, n=6) and *villin-gp130^Act/Yap^ΔIEC* (○, n=4) mice was examined by H&E staining and scored 9 days after 2.0% DSS challenge by an observer blinded to the mouse genotype. Results are averages ± SEM. *P < 0.05. Right: Body weight curves of DSS-treated *Stat3^ΔIEC* (□) and *villin-gp130^Act/Stat3^ΔIEC* (○) mice (n=4/group). Results are averages ± SD. *P < 0.05. Mucosal histology of *Stat3^ΔIEC* and *villin-gp130^Act/Stat3^ΔIEC* mice (n=4/group) was examined and scored 8 days after 2.0% DSS challenge as above. Results are averages ± SEM. *P < 0.05. (b) RNA was extracted from *Yap^ΔIEC* and *villin-gp130^Act/Yap^ΔIEC* (n=3/group) or *Stat3^ΔIEC* and *villin-gp130^Act/Stat3^ΔIEC* (n=4/group) colons, and expression of the indicated mRNA species was measured by qRT-PCR. Results are averages ± SEM. *P < 0.05. (c) IEC6 rat intestinal epithelial cells transfected with either empty (EV) or gp130^Act expression vector were grown to confluence and starved overnight, and the monolayers were wounded by scratching and treated with DMSO, PP2 (10 μM), AZD1480 (1 μM), verteporfin (1 μg/ml) or DBZ (10 μM). The percent wounded area was calculated by measuring wound closure over time (0 and 24 hours). Results are averages ± SEM. *P < 0.05. (n=5). (d) Total cell lysates of IEC6 cells transfected with empty vector (EV) + shluc (control), gp130^Act + shluc or gp130^Act + shYAP were prepared, and subjected to IB analysis with the indicated antibodies. (e) IEC6 cells transfected with empty vector (EV) + shluc (control), gp130^Act + shluc or gp130^Act + shYAP were grown to confluence and starved overnight, and the monolayers were wounded by scratching. The percent wounded area was calculated by measuring wound closure over time (0 and 24 hours) (n=5). Results are averages ± SEM. *P < 0.05. (f) Schematic representation of the gp130-SFK-YAP-Notch pathway and its function in the injured intestinal epithelium. Scale bars represent 100 μm (a).

**Figure 1. Persistent gp130 activation causes aberrant IEC proliferation and differentiation**
(a) Wild-type (WT) and *villin-gp130^Act* (Tg) small intestine lengths at 3 months (n=5). Data represent averages ± SEM. *P < 0.05. (b) Hematoxylin and eosin (H&E) staining of paraffin-embedded small intestinal sections from WT and Tg mice. Shown are representative images. (**c, e–g**) Immunohistochemical (IHC) analysis of paraffin-embedded small intestinal sections from WT and Tg mice (n=6). Ki67 and BrdU incorporation (c), Alcian blue (AB)+MMP7 and chromogranin A (ChrA) (e), Wheat germ agglutinin (WGA) (f), and alkaline phosphatase (AP) and DAPI (g) stainings. (d) Ki67 and BrdU positive cells were counted in each crypt. Data are averages ± SD. *P < 0.05. Scale bars represent 100 μm (**b, c, e–g**).

**Figure 2. gp130 activates YAP and Notch signaling**
(a) Lysates of WT and Tg jejuna were analyzed for expression and phosphorylation of the indicated proteins. (b) P-STAT3, YAP and HES1 stainings of paraffin-embedded small intestinal sections (n=6). Positive cells were enumerated in each villus or crypt. Data are averages ± SD. *P < 0.05. (**c, d**) WT and Tg small intestinal organoids stained with YAP (c) and CD44 C-terminal (d) antibodies were examined by immunofluorescent (IF) microscopy. Scale bars represent 100 μm (**b–d**) and all data are representative of at least 2-3 independent experiments.

**Figure 3. Notch or YAP inhibition partially restores tissue homeostasis**
(**a, b**) PAS, Ki67, YAP and HES1 stainings of paraffin-embedded small intestinal sections from control and DBZ (10 μmol/kg)-treated Tg mice (n=3/group). Positive cells were enumerated in each villus or crypt (b). Data are averages ± SD. *P < 0.05. (**c, d**) Paraffin-embedded small intestinal sections from *villin-gp130^Act* and *villin-gp130^Act/Yap^ΔIEC* mice (n=4/group) were stained and quantified as above (d). Data are averages ± SD. *P < 0.05. (e) Lysates of *villin-gp130^Act* and *villin-gp130^Act/Yap^ΔIEC* jejuna were analyzed for the indicated proteins. Scale bars represent 100 μm (**a, c**) and all data are representative of at least 2–3 independent experiments.

**Figure 4. SFK activate YAP downstream to gp130^Act and are active in human IBD**
(a) IHC of activating (Y419) and inhibitory (Y530) Src phosphorylation in paraffin-embedded small intestinal sections from WT and Tg mice. (b) WT and Tg small intestinal organoids were lysed and analyzed for expression and phosphorylation of the indicated proteins. (c) Tg mice (n=4/group) were treated with PP2 (5 mg/kg) or vehicle once a day for 5 days. Small intestinal sections were stained as indicated. Positive cells were enumerated in each villus or crypt. Data are averages ± SD. *P < 0.05. (d) Normal (n=11) and CD (n=18) human colon biopsies were fixed, sectioned and stained as indicated. Src and YAP activation were found in 11/18 CD specimens in areas with active disease. (e) Co-immunoprecipitation (IP) of endogenous gp130, SFK and YAP in HT29 cells. Cells were collected with or without 2 hr IL-6 (10 ng/ml) stimulation. Lysates were IP’ed with gp130 (left) or Src (right) antibodies or corresponding IgG controls and probed with the indicated antibodies. (f) Total cell lysates of T84 colon cancer cells transfected with empty vector (EV), gp130^Act, gp130^Act(Δ771-811) or gp130^Act(Δ812-827) expression vectors were prepared and subjected to IB analysis with the indicated antibodies. (g) WT and Tg small intestinal organoids were treated with DMSO and PP2 (10 μM) for 24 hrs, stained with YAP antibody and counter stained with DAPI. Scale bars represent 100 μm (**a, c, d, g**) and all data are representative of at least 2–3 independent experiments.

**Figure 5. gp130-SFK-YAP signaling is activated upon mucosal erosion to promote regeneration**
(a) Body weight curves and day 10 histological scores of DSS-treated WT (□) and Tg (○) mice (n=4/group). Results are averages ± SD. *P < 0.05. (b) Ki67 (upper panels) and cleaved-caspase3 (lower panels) stainings of colon sections from WT and Tg mice at day 0 and 3 (Ki67) or 5 (cleaved-caspase3) after 3.0% DSS treatment. Positive cells were enumerated in representative microscopic fields (magnification 200 × for Ki67 and 100 × for cleaved-caspase3) (n=6) per time point. Results are averages ± SEM. *P < 0.05. (c) WT and Tg mice were treated as above. Colonic lysates were prepared when indicated and IB analyzed for indicated proteins. (d) Lysates of *Yap^ΔIEC* and *villin-gp130^Act/Yap^ΔIEC,* or *Stat3^ΔIEC* and *villin-gp130^Act/Stat3^ΔIEC* colons were prepared, and IB analyzed with the indicated antibodies. Data were quantified using ImageJ software and are depicted on right as averages ± SEM (n=3/group). *P < 0.05. (e) Body weight curves of DSS-treated control (□) and PP2-injected (5 mg/kg) (○) C57BL/6 mice (n=6/group). Results are averages ± SD. *P < 0.05. (f) Mucosal histology of above mice was scored at day 10 of DSS challenge by H&E staining. Results are averages ± SEM. *P < 0.05. Scale bars represent 100 μm. (g) Body weight curves and day 9 histological scores of *villin-gp130^Act* (○), *villin-gp130^Act/Yap^ΔIEC* (□) and *villin-gp130^Act/Stat3^ΔIEC* (◇) mice treated with 2.5% DSS (n=5/group). Results are averages ± SD (body weight curves) or averages ± SEM (histological scores). *P < 0.05: *villin-gp130^Act* vs *villin-gp130^Act*/*Yap^ΔIEC* mice. #P < 0.05: *villin-gp130^Act* vs *villin-gp130^Act*/*Stat3^ΔIEC* mice.

See this image and copyright information in PMC

References

1. Ben-Neriah Y, Karin M. Inflammation meets cancer, with NF-kappaB as the matchmaker. Nat Immunol. 2011;12:715–723. doi: 10.1038/ni.2060. - DOI - PubMed
1. Medzhitov R. Origin and physiological roles of inflammation. Nature. 2008;454:428–435. doi: 10.1038/nature07201. - DOI - PubMed
1. Baddour JA, Sousounis K, Tsonis PA. Organ repair and regeneration: an overview. Birth defects research. Part C, Embryo today : reviews. 2012;96:1–29. doi: 10.1002/bdrc.21006. - DOI - PubMed
1. Johnson R, Halder G. The two faces of Hippo: targeting the Hippo pathway for regenerative medicine and cancer treatment. Nature reviews. Drug discovery. 2014;13:63–79. doi: 10.1038/nrd4161. - DOI - PMC - PubMed
1. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell. 2010;140:883–899. doi: 10.1016/j.cell.2010.01.025. - DOI - PMC - PubMed

Publication types

Actions
Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Grants and funding

LinkOut - more resources

Full Text Sources
Other Literature Sources
- The Lens - Patent Citations Database
- scite Smart Citations
Molecular Biology Databases
Research Materials
- Addgene Non-profit plasmid repository
- GeneTex Inc
Miscellaneous
- NCI CPTAC Assay Portal

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

A gp130-Src-YAP module links inflammation to epithelial regeneration

Affiliations

A gp130-Src-YAP module links inflammation to epithelial regeneration

Authors

Affiliations

Abstract

Figures

References

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources

Full Text Sources

Other Literature Sources

Molecular Biology Databases

Research Materials

Miscellaneous